Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 2, 2011, Pages 408-413

  Goyal, Sharad ^a   Rao, Malay S ^a   Khan, Atif ^a   Huzzy, Lien ^a   Green, Camille ^a   Haffty, Bruce G ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Acute locoregional toxicity; Bevacizumab (Avastin); Breast cancer; Combined modality therapy; Radiation therapy

Indexed keywords

ACUTE LOCOREGIONAL TOXICITY; BEVACIZUMAB; BREAST CANCER; COMBINED MODALITY THERAPY; RADIATION THERAPY;

CONCURRENCY CONTROL; TOXICITY; WALLS (STRUCTURAL PARTITIONS);

RADIOTHERAPY;

BEVACIZUMAB; TRASTUZUMAB;

ADULT; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATITIS; DRUG FATALITY; FATIGUE; FIBROSIS; HEART EJECTION FRACTION; HUMAN; LYMPHEDEMA; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION FIBROSIS; RADIATION INJURY; SKIN MANIFESTATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FATIGUE; FEMALE; HUMANS; LYMPHEDEMA; MIDDLE AGED; PNEUMONIA; RADIATION PNEUMONITIS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT;

EID: 78650811722     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.11.021     Document Type: Article

References (18)

1. C. Nieder, N. Wiedenmann, and N. Andratschke Current status of angiogenesis inhibitors combined with radiation therapy Cancer Treat Rev 32 2006 348 364
2. M.A. Cobleigh, V.K. Langmuir, and G.W. Sledge A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer Semin Oncol 30 2003 117 124
3. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
4. D.H. Johnson, L. Fehrenbacher, and W.F. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191
5. L.B. Saltz, S. Clarke, and E. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study J Clin Oncol 26 2008 2013 2019
6. T.Y. Seiwert, D.J. Haraf, and E.E. Cohen Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer J Clin Oncol 26 2008 1732 1741
7. J.C. Yang, L. Haworth, and R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
8. P.E. Huber, M. Bischof, and J. Jenne Trimodal cancer treatment: Beneficial effects of combined antiangiogenesis, radiation, and chemotherapy Cancer Res 65 2005 3643 3655
9. A.J. Schueneman, E. Himmelfarb, and L. Geng SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models Cancer Res 63 2003 4009 4016
10. A.D. Norden, J. Drappatz, and P.Y. Wen Novel anti-angiogenic therapies for malignant gliomas Lancet Neurol 7 2008 1152 1160
11. C.H. Crane, L.M. Ellis, and J.L. Abbruzzese Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer J Clin Oncol 24 2006 1145 1151
12. L.B. Jakeman, J. Winer, and G.L. Bennett Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues J Clin Invest 89 1992 244 253
13. S. Ning, D. Laird, and J.M. Cherrington The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation Radiat Res 157 2002 45 51
14. K.J. Williams, B.A. Telfer, and S. Brave ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity Clin Cancer Res 10 2004 8587 8593
15. C.H. Crane, K. Winter, and W.F. Regine Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411 J Clin Oncol 27 2009 4096 4102
16. L.B. Marks, X. Yu, and R.G. Prosnitz The incidence and functional consequences of RT-associated cardiac perfusion defects Int J Radiat Oncol Biol Phys 63 2005 214 223
17. K. Pistevou-Gompaki, A. Hatzitolios, and N. Eleftheriadis Evaluation of cardiotoxicity five years after 2D planned, non-simulated, radiation therapy for left breast cancer Ther Clin Risk Manag 4 2008 1359 1362
18. C.G. Willett, D.G. Duda, and E. di Tomaso Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study J Clin Oncol 27 2009 3020 3026